|
◇Daehwa Pharm Gains Momentum on Rapid Growth in China with 'Liporaxel'
According to KG Zeroin's MP DOCTOR, the representative pharmaceutical and biotech stocks listed among the top 30 gainers of the day were Daehwa Pharmaceutical, LabGenomics, and NeoImmuneTech. Their share prices surged by 13.05% (closing at 10,740 KRW), 12.50% (882 KRW), and 12.01% (1,529 KRW), respectively, capturing significant market attention.
Daehwa Pharmaceutical's upward trajectory was driven primarily by overseas sales centered on the Chinese market. The company clearly demonstrated through its quarterly earnings that its global market expansion is delivering tangible results.
Daehwa Pharm announced on the same day that its second-quarter consolidated revenue reached 41.3 billion KRW, up 15% from 36.0 billion KRW in the same period last year. Notably, profitability saw a dramatic turnaround. Operating profit rose approximately 11.7-fold, climbing from 300 million KRW to 3.3 billion KRW. The operating profit margin jumped from 0.8% to 8.1%, and net income turned profitable at 2.0 billion KRW, recovering from a net loss of 500 million KRW in the prior-year period.
The main driver behind this strong performance was the full-scale supply of 'Liporaxel Solution,' an oral paclitaxel anticancer drug, in China. Under its supply agreement with Chinese partner RMX Biopharma, Daehwa Pharm delivered 9.7 billion KRW worth of Liporaxel in the first half of the year alone. After obtaining marketing approval as a gastric cancer treatment in China in September 2024, Liporaxel was included in the National Reimbursement Drug List (NRDL) in December 2025, with national insurance coverage taking effect in January this year.
Consequently, Daehwa Pharm's first-half sales in China soared to 10.1 billion KRW, more than a fivefold increase compared to approximately 1.8 billion KRW in the same period last year. Total consolidated exports for the first half reached 17.4 billion KRW, already surpassing the full-year export total of 16.6 billion KRW recorded last year.
Moving forward, the key factor will be whether expanding prescriptions for Liporaxel in China leads to sustained additional orders. Furthermore, having secured an additional indication from South Korea's Ministry of Food and Drug Safety (MFDS) in May for first-line treatment of recurrent or metastatic HER2-negative breast cancer, the company's ability to expand into breast cancer indications and deliver global clinical outcomes will be pivotal for its future valuation.
"Liporaxel Solution is rapidly establishing its presence not only domestically but also in international markets," a Daehwa Pharm official said. "We will continue to drive patient-centered innovation through indication expansions and global development."
|
◇LabGenomics Accelerates 'Global Diagnostics' via US Operations Consolidation and Licensing Deal
For LabGenomics, a molecular diagnostics company specializing in genomics, the main catalyst for its stock surge was an exclusive US licensing agreement in the cancer diagnostics domain signed with liquid biopsy firm Dxome through its US subsidiary, LabGenomics. Under the agreement, LabGenomics (US) will exclusively supply three high-value diagnostic services to the US market: the 'Hema655' hematologic malignancy panel, the 'MRD30' minimal residual disease panel, and the 'Lymphoma-ctDNA' circulating tumor DNA panel.
In particular, Dxome's proprietary liquid biopsy platform 'PiSeq,' developed by a team from Severance Hospital's Department of Laboratory Medicine, prevents data loss during processing and significantly enhances variant detection accuracy. By integrating Dxome's precision molecular diagnostics into its existing flow cytometry, cytogenetics, and NGS panels, LabGenomics has built a comprehensive blood cancer diagnostic portfolio covering cell analysis, chromosome testing, genetic screening, and post-treatment monitoring. Possessing testing networks across 27 US states and established distribution channels with Integrated Delivery Networks (IDNs) such as Sutter Health, rapid commercialization is anticipated.
The consolidation of its local sales network also positively influenced investor sentiment. After acquiring US Clinical Laboratory Improvement Amendments (CLIA) labs QDx in 2023 and IMD in 2024, LabGenomics recently unified them under a single brand, 'LabGenomics.'
On the 4th, the company held a 'National Sales Meeting' at its New Jersey laboratory, gathering nationwide sales personnel and doubling its sales force. The company also appointed Tim Murray, a 20-year veteran in diagnostic laboratory sales, as Vice President of Sales to streamline cross-selling and reorganize regional sales structures.
Market observers expect cost efficiencies from eliminating duplicate infrastructure and revenue rebound effects from brand consolidation to materialize in the second half of the year. Whether top-line growth at the US subsidiary directly translates into expanded scale and profitability for the parent company will be a crucial benchmark going forward.
"We will be able to deliver differentiated hematologic cancer diagnostic services to the US market," a LabGenomics official stated. "Based on our complete diagnostic framework—spanning cell analysis, genetic testing, and follow-up monitoring—we aim to enhance overall profitability."
|
◇NeoImmuneTech Seeks Rebound Through New Revenue Stream and Financial Stability Emphasis
NeoImmuneTech gained market favor as its preliminary efforts to turn around its business performance were positively received. Previously, NeoImmuneTech disclosed the voluntary withdrawal of its Phase 2 clinical trial (NIT-119) for 'NT-I7' (efineptakin alfa, a long-acting interleukin-7) in non-small cell lung cancer (NSCLC) due to delayed patient recruitment and the expiration of a joint supply agreement with Roche. As multiple company-sponsored trials in glioblastoma, skin cancer, and gastric cancer were previously discontinued, market trust had taken a hit. Currently, company-led clinical trials have been streamlined primarily to a Phase 1b/2a solid tumor trial in the US and acute radiation syndrome (ARS) studies.
Amid ongoing uncertainty in its core pipeline development, the company sought a breakthrough during an investor presentation in July by outlining plans to secure at least one licensing-out deal within the year and stabilize finances through new revenue sources.
The most notable initiative is the US commercialization of 'Endari,' a treatment for sickle cell disease. After acquiring a drug distribution license in Maryland in May, NeoImmuneTech initiated distribution. Leveraging top US pharmaceutical wholesalers—McKesson, Cencora, and Cardinal Health—the company targets annual sales exceeding $8 million (approx. 11.3 billion KRW). This revenue is intended to buffer R&D expenses while creating distribution and insurance networks that can later support the commercialization of NT-I7.
Additionally, the company reported having 45.0 billion KRW in available cash as of late June, asserting that under its current development plan, operations can be sustained through 2027 without additional capital raises or shareholder dilution. Operating expenses have also been drastically reduced from 55.6 billion KRW in 2023 to 25.3 billion KRW in 2025, and 6.7 billion KRW in Q1 2026.
NeoImmuneTech's valuation recovery will ultimately depend on achieving its $8 million annual target for Endari, executing early licensing-out for its investigator-initiated trial combining NT-I7 with CAR-T therapies (NIT-126), and securing momentum with US government (BARDA) contracts and ARS drug approval timelines.
"For the ARS treatment, we expect to secure final primate study data as early as the end of this year," a NeoImmuneTech representative noted. "However, the exact timing may vary depending on the outcomes of other priority tasks.“
Copyright ⓒ 이데일리 무단 전재 및 재배포 금지
본 콘텐츠는 뉴스픽 파트너스에서 공유된 콘텐츠입니다.
다음 내용이 궁금하다면?
광고 보고 계속 읽기
원치 않을 경우 뒤로가기를 눌러주세요
